company background image
LCT

Living Cell TechnologiesASX:LCT Stock Report

Market Cap

AU$6.4m

7D

-10.0%

1Y

-35.7%

Updated

26 Oct, 2021

Data

Company Financials
LCT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LCT Overview

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand.

Price History & Performance

Summary of all time highs, changes and price drops for Living Cell Technologies
Historical stock prices
Current Share PriceAU$0.009
52 Week HighAU$0.009
52 Week LowAU$0.025
Beta0.73
1 Month Change-10.00%
3 Month Change-30.77%
1 Year Change-35.71%
3 Year Change-81.25%
5 Year Change-88.75%
Change since IPO-96.40%

Recent News & Updates

Jan 07
How Does Living Cell Technologies' (ASX:LCT) CEO Pay Compare With Company Performance?

How Does Living Cell Technologies' (ASX:LCT) CEO Pay Compare With Company Performance?

This article will reflect on the compensation paid to Ken Taylor who has served as CEO of Living Cell Technologies...

Shareholder Returns

LCTAU BiotechsAU Market
7D-10.0%-0.09%0.8%
1Y-35.7%3.7%24.4%

Return vs Industry: LCT underperformed the Australian Biotechs industry which returned 3.7% over the past year.

Return vs Market: LCT underperformed the Australian Market which returned 24.4% over the past year.

Price Volatility

Is LCT's price volatile compared to industry and market?
LCT volatility
LCT Beta0.73
Industry Beta1.64
Market Beta1

Stable Share Price: LCT is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: LCT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1987n/aBernie Tuchhttps://www.lctglobal.com

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson’s disease. The company was founded in 1987 and is based in Melbourne, Australia.

Living Cell Technologies Fundamentals Summary

How do Living Cell Technologies's earnings and revenue compare to its market cap?
LCT fundamental statistics
Market CapAU$6.42m
Earnings (TTM)-AU$1.46m
Revenue (TTM)AU$268.18k

24.3x

P/S Ratio

-4.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LCT income statement (TTM)
RevenueAU$268.18k
Cost of RevenueAU$0
Gross ProfitAU$268.18k
ExpensesAU$1.73m
Earnings-AU$1.46m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.002
Gross Margin100.00%
Net Profit Margin-544.62%
Debt/Equity Ratio0.0%

How did LCT perform over the long term?

See historical performance and comparison

Valuation

Is Living Cell Technologies undervalued compared to its fair value and its price relative to the market?

4.69x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LCT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LCT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LCT is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: LCT is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LCT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LCT is good value based on its PB Ratio (4.7x) compared to the AU Biotechs industry average (4.9x).


Future Growth

How is Living Cell Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Living Cell Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Living Cell Technologies performed over the past 5 years?

24.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LCT is currently unprofitable.

Growing Profit Margin: LCT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LCT is unprofitable, but has reduced losses over the past 5 years at a rate of 24.7% per year.

Accelerating Growth: Unable to compare LCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (48%).


Return on Equity

High ROE: LCT has a negative Return on Equity (-106.06%), as it is currently unprofitable.


Financial Health

How is Living Cell Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: LCT's short term assets (A$1.6M) exceed its short term liabilities (A$265.1K).

Long Term Liabilities: LCT has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: LCT is debt free.

Reducing Debt: LCT has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LCT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LCT has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 12.5% each year.


Dividend

What is Living Cell Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LCT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LCT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LCT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Bernie Tuch (70 yo)

0.25

Tenure

AU$68,542

Compensation

Dr. Bernard Tuch, also known as Bernie, BSc, MBBS (Hons), FRACP, Ph D., GAICD, has been an Interim Chief Executive Officer at Living Cell Technologies Limited since July 16, 2021. He has been the Chairman...


Leadership Team

Experienced Management: LCT's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: LCT's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.9%.


Top Shareholders

Company Information

Living Cell Technologies Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Living Cell Technologies Limited
  • Ticker: LCT
  • Exchange: ASX
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$6.425m
  • Shares outstanding: 713.85m
  • Website: https://www.lctglobal.com

Location

  • Living Cell Technologies Limited
  • 330 Collins Street
  • Level 7
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 07:02
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.